| Original language | English (US) |
|---|---|
| Pages (from-to) | 677-679 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 83 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 2020 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, Vol. 83, No. 2, 08.2020, p. 677-679.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics
T2 - A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
AU - Wan, Marilyn T.
AU - Shin, Daniel B.
AU - Winthrop, Kevin L.
AU - Gelfand, Joel M.
N1 - Funding Information: Conflicts of interest: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie , Janssen , Novartis Corp , Sanofi , Celgene , Ortho Dermatologics , and Pfizer Inc , and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics . In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Wan is supported in part by a grant from Pfizer . Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer , and is a consultant for UCB, AbbVie, Eli Lilly and Company, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Funding Information: Funding sources: Supported in part by a grant (P30-AR0-69589-03) from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand.Conflicts of interest: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer, and is a consultant for UCB, AbbVie, Eli Lilly and Company, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Funding Information: Funding sources: Supported in part by a grant ( P30-AR0-69589-03 ) from the National Institutes of Health , National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand.
PY - 2020/8
Y1 - 2020/8
UR - http://www.scopus.com/inward/record.url?scp=85087304353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087304353&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.05.035
DO - 10.1016/j.jaad.2020.05.035
M3 - Article
C2 - 32416207
AN - SCOPUS:85087304353
SN - 0190-9622
VL - 83
SP - 677
EP - 679
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -